Bilayer Tablet Segmentation for Ezetimibe and Rosuvastatin Dissolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing pharmaceutical compositions containing ezetimibe and rosuvastatin suffer from pharmaceutical interactions that decrease the dissolution of ezetimibe, making it difficult to meet therapeutic criteria and regulatory requirements, especially when formulated together in a bilayer tablet or with a common excipient system.
Innovation Solution
The composition separates ezetimibe and rosuvastatin into individual physical phases with minimal surface contact, allowing for controlled release by varying disintegration times, and includes a surfactant like sodium lauryl sulfate to enhance solubility, ensuring at least 80% dissolution within 30 minutes, and using microcrystalline cellulose, colloidal silica, and magnesium stearate to maintain stability and strength.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If ezetimibe and rosuvastatin are formulated together in a combined pharmaceutical composition, then the convenience of administration is improved, but the dissolution of ezetimibe decreases due to pharmaceutical interactions
Solution Approach 1:
The patent divides the combined pharmaceutical composition into two separate layers: a first layer containing ezetimibe and a second layer containing rosuvastatin. This segmentation prevents direct contact between the two active ingredients, thereby eliminating the pharmaceutical interaction that would otherwise decrease ezetimibe dissolution, while still providing the convenience of a single combined dosage form for administration.
2Ease of manufacture
If ezetimibe and rosuvastatin are formulated in the same physical phase, then the manufacturing process is simplified, but the stability of the active ingredients deteriorates due to pharmaceutical interactions
Solution Approach 1:
The patent creates two distinct physical phases or layers within the tablet: a first layer for ezetimibe and a second layer for rosuvastatin. This segmentation maintains stability by preventing direct interaction between the active ingredients while still allowing for a relatively simple manufacturing process using conventional tabletting equipment and techniques.
3Device complexity
If a common excipient system is used for both active ingredients, then the formulation complexity is reduced, but the dissolution performance of ezetimibe deteriorates
Solution Approach 1:
The patent assigns different excipient systems to each layer: the first layer contains ezetimibe with excipients optimized for its dissolution (including surfactants like sodium lauryl sulfate), while the second layer contains rosuvastatin with its own excipient system. This segmentation allows each active ingredient to have its dissolution requirements met without compromising the other, while the layered structure keeps the overall formulation manageable.
4Speed
If the disintegration time of the tablet is reduced to improve dissolution, then the dissolution speed is improved, but the structural integrity of the tablet deteriorates
Solution Approach 1:
The patent creates a layered tablet structure where each layer can be optimized independently. The first layer containing ezetimibe can be formulated with excipients and properties that promote rapid disintegration and dissolution, while the second layer containing rosuvastatin can be formulated to maintain structural integrity. The layered design allows the tablet to disintegrate in a controlled manner, with each layer contributing to the overall structural strength while enabling fast dissolution of the active ingredients.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach minimizes pharmaceutical interactions, ensures stable and rapid dissolution of both active ingredients, meeting therapeutic objectives and regulatory standards, and demonstrates bioequivalence in pharmacokinetic studies compared to commercial products.
Implementation Method 1
includes a surfactant like sodium lauryl sulfate to enhance solubility
Data Source
AI summary
The present invention is related to a pharmaceutical composition containing rosuvastatin and ezetimibe, wherein the interaction of the active ingredient and excipient is minimized, the active ingredients are present in spatially separated or contacting physical phases and wherein the active ingredient release from the two phases takes place in temporarily separated manner rather than occuring at the same time or begins delayed from one phase compared to the other, other. A further aspect of the present invention is method for decreasing an active ingredient- excipient interaction or interaction between active ingredients in combined pharmaceutical composition containing several solid phases produced by compression, which comprises adjusting the disintegration time of the compressed solid phases different from each other.